Recently, the first drug-coated vascular coated stent for central venous lesions in China, a national prospective, multicenter, randomized controlled clinical trial with the Department of Vascular Surgery of West China Hospital of Sichuan University as the co-leader, was completed by the team of Prof. Zhao Jichun of the Department of Vascular Surgery and Prof. Cui Tianlei of the Department of Nephrology of West China Hospital of Sichuan University. The first case enrolled in our center marked the clinical trial project entered the full implementation stage.
According to statistics, by the end of 2022, the total number of dialysis in China reached 1 million, of which more than 800,000 were hemodialysis patients. Central venous stenosis or occlusion is one of the major complications of hemodialysis patients, which seriously affects the quality of dialysis for patients. Currently, the preferred treatment is endoluminal treatment, and most of them adopt intravascular luminal balloon dilatation treatment, but with simple balloon dilatation, the blood vessels are prone to retraction and restenosis and thrombosis, and the long-term patency is poor, and currently there is a lack of laminar stents for central venous stenosis on the market in China.
Comparison of preoperative and postoperative images of the patient
A prospective, multicenter, randomized controlled clinical trial of the safety and efficacy of a drug-coated vascular overlay stent system for the treatment of central venous stenosis or occlusive lesions was conducted by the West China Hospital of Sichuan University and the First Affiliated Hospital of Chongqing Medical University as the co-leaders of the trial, which included 10 participating units, including the Guangdong Provincial People's Hospital, the Gaozhou City People's Hospital, the First Affiliated Hospital of Guangxi Medical University, the Affiliated Tumor Hospital of Guizhou Medical University, the Guilin The Affiliated Hospital of Guizhou Medical University, Guilin Medical College Hospital, Suzhou Municipal Hospital, Wuhan Central Hospital, and Shaw Hospital of Zhejiang University are the 10 participating units, and 154 subjects are planned to be included in the randomized controlled clinical trial.
专家介绍
Prof. Jichun Zhao
Chief Physician, Professor
Supervisor of doctoral students
Director of Vascular Surgery, West China Hospital, Sichuan University
Executive Director of the Chinese Society of Geriatrics and President of the Peripheral Vascular Disease Management Branch
Vice Chairman of Vascular Surgery Physicians Branch, Chinese Medical Doctors Association (CMA)
Vice Chairman of the Vascular Surgery Committee of the National Specialized Committee on Cardiovascular Diseases (NSCVD)
Vice President, Asia-Pacific Vascular Academic Alliance
Vice President, International Vascular Federation China
Vice Chairman, Specialized Committee on Retroperitoneal and Pelvic Floor Diseases, Chinese Research Hospitals
Academic Committee of the National Center for Clinical Research on Radiation and Therapy (NCCRT)
Member of Chinese Medical Association Vascular Surgery Group
Academic and Technical Leaders of Sichuan Province
Sichuan Province "Tianfu Qingcheng Program" Tianfu Famous Doctors
President of Sichuan Physicians Association Vascular Surgery Physicians Branch
Chairman, Vascular Surgery Group, Sichuan Provincial Medical Association
He is the deputy editor-in-chief of Chinese Basic and Clinical Journal of General Surgery, Journal of Vascular and Endoluminal Vascular Surgery, Chinese Journal of Vascular Surgery (Electronic Edition), and deputy editor-in-chief of Chinese Journal of Vascular Surgery. He has been awarded 3 first prizes and 1 second prize for provincial scientific and technological progress achievements, and has received national, ministerial and provincial funding. He has published more than 230 academic papers, including more than 90 SCI papers.
In the diagnosis, surgery and minimally invasive endoluminal vascular treatment of vascular surgical diseases, especially in ruptured abdominal aortic aneurysm surgery and endoluminal treatment, high-risk abdominal aortic aneurysm surgery and endoluminal repair, surgical and endoluminal hybridization of thoracic and abdominal aortic aneurysm and coarctation, surgical treatment of complex carotid artery aneurysm, peripheral vascular disease in diabetic foot, thrombosed arterial vein-related diseases and retroperitoneal tumor resection and arterial reconstruction involving large blood vessels. The research on arterial reconstruction for liver transplantation is in-depth and at an advanced level both at home and abroad.
Reprinted from Hi-Hearts
